DHA and EPA (cas 10417-94-4) nanoemulsions prEPA (cas 10417-94-4)red by the low-energy emulsification method: Process factors influencing droplet size and physicochemical stability
-
Add time:08/01/2019 Source:sciencedirect.com
To extend the application of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA (cas 10417-94-4)) in liquid food, and to improve the physicochemical stability, we prepared stable DHA and EPA nanoemulsions, which can be used for large scale production. The Emulsion Phase Inversion (EPI) method was used to prepare nanoemulsions as safe and convenient with low-energy emulsification method. The type of oil, the type of surfactant and the concentration of surfactant have the most significant effect on particle size. Within 20 days, the nanoemulsions have good physical stability under different storage conditions, and the retention rate of DHA/EPA can be stabilized at >60%. Furthermore, different types of natural antioxidants were added and the effect was detected by analyzing the peroxide value. Among them, tea polyphenols showed the most significant effect. The data obtained showed enhanced nanoemulsions stability, increased application in food and actual large-scale production.
We also recommend Trading Suppliers and Manufacturers of EPA (cas 10417-94-4). Pls Click Website Link as below: cas 10417-94-4 suppliers
Prev:A comparative study about EPA (cas 10417-94-4)-PL and EPA (cas 10417-94-4)-EE on ameliorating behavioral deficits in MPTP-induced mice with Parkinson’s disease by suppressing oxidative stress and apoptosis
Next:The utility of nutritional supportive care with an eicosapentaenoic acid (EPA (cas 10417-94-4))-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The utility of nutritional supportive care with an eicosapentaenoic acid (EPA (cas 10417-94-4))-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study08/02/2019
- A comparative study about EPA (cas 10417-94-4)-PL and EPA (cas 10417-94-4)-EE on ameliorating behavioral deficits in MPTP-induced mice with Parkinson’s disease by suppressing oxidative stress and apoptosis07/31/2019


